Apolizumab

Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro[1][2].

Product Specifications

CAS Number

[267227-08-7]

Product Name Alternative

Hu1D10

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/apolizumab.html

Solubility

10 mM in DMSO

Smiles

[Apolizumab]

References & Citations

[1]Thomas S Lin, et al. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50 (12) :1958-63.|[2]Matthew L. Hill DO, et al. In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines. Volume 106, Issue 11, 16 November 2005, Page 4826.